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Abstract
Introduction: Collagen-induced arthritis (CIA) is a mouse model for rheumatoid arthritis (RA) and is induced after
immunization with type II collagen (CII). CIA, like RA, is an autoimmune disease leading to destruction of cartilage
and joints, and both the priming and inflammatory phases have been suggested to be dependent on proteases. In
particular, the cysteine proteases have been proposed to be detrimental to the arthritic process and even
immunomodulatory. A natural inhibitor of cysteine proteases is cystatin C.
Methods: Cystatin C-deficient, sufficient and heterozygous mice were tested for onset, incidence and severity of
CIA. The effect of cystatin C-deficiency was further dissected by testing the inflammatory effector phase of CIA; that
is, collagen antibody-induced arthritis model and priming phase, that is, T cell response both in vivo and in vitro.I n
addition, in order to determine the importance of T cells and antigen-presenting cells (APCs), these cell
populations were separated and in vitro T cell responses determined in a mixed co-culture system. Finally, flow
cytometry was used in order to further characterize cell populations in cystatin C-deficient mice.
Results: Here, we show that mice lacking cystatin C, develop arthritis at a higher incidence and an earlier onset
than wild-type controls. Interestingly, when the inflammatory phase of CIA was examined independently from
immune priming then cystatin C-deficiency did not enhance the arthritis profile. However, in line with the
enhanced CIA, there was an increased T cell and B cell response as delayed-type hypersensitivity reaction and anti-
CII antibody titers were elevated in the cystatin C-deficient mice after immunization. In addition, the ex vivo naïve
APCs from cystatin C-deficient mice had a greater capacity to stimulate T cells. Interestingly, dendritic cells had a
more activated phenotype in naïve cystatin C-deficient mice.
Conclusions: The lack of cystatin C enhances CIA and primarily affects in vivo priming of the immune system.
Although the mechanism of this is still unknown, we show evidence for a more activated APC compartment, which
would elevate the autoimmune response towards CII, thus resulting in an enhanced development of chronic arthritis.
Introduction
Rheumatoid arthritis (RA) is a chronic inflammatory
disease causing cartilage and bone destruction in the
joints. Interestingly, it is believed that in the inflamed
joint the papain-like cysteine proteases, especially cathe-
psin B, H, L, S and K contribute to the tissue damage
[1-5]. Hence, cysteine proteases have been highlighted
as potential drug targets to treat tissue degenerative and
inflammatory processes [6]. The degradation of the tis-
sue in the joints is clearly mediated by proteolytic activ-
ities; however, the specific roles of the different enzymes
are still largely unknown. Under physiological conditions
the protease activity of these papain-like cysteine pro-
teases are regulated by the cystatins. Cystatin C belongs
to the cystatin superfamily 2 and is a potent inhibitor of
cathepsins B, H, K, L and S. It is a secreted protein, pro-
duced by most nucleated cell types; hence, it is present
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secreted protein, its major site of function is in the
extracellular compartment [7,8].
Cystatins, and in particular cystatin C, have been
shown to be involved in many biological events and
have not always been related to protease inhibition;
examples include a neural stem cell factor [9], osteoclast
differentiation [10], pathophysiological process in brain
ischemia [11] as well as in atherosclerotic plaque devel-
opment [12,13]. In relation to arthritis, cystatin C has
been found to be the most prominent cystatin in syno-
vial fluid of RA patients and that RA patients have sig-
nificantly lowered levels of cystatin C in circulation [14].
In addition, cystatin C has been shown to enhance
fibroblast and smooth muscle cell proliferation and neu-
trolphil function [15-17]. With this diverse range of pos-
sible functions of cystatin C we wished to investigate
cystatin C involvement in an in vivo autoimmune pro-
cess in a well-defined animal model.
Collagen induced arthritis (CIA) has been extensively
used as an animal model for human RA, and is induced
by immunization with type II collagen (CII). Develop-
ment of CIA has been shown to be B and T cell depen-
dent [18-20]. Furthermore, T cell responses to CII and,
consequently, susceptibility to CIA is genetically linked
to the MHC class II A
q molecule [21]. Interestingly,
cathepsin K is one of the few proteases with the capacity
to degrade native collagen type I and II [22]. Antigen pre-
sentation is an important requirement for the immune
response and, indeed, in CIA, the efficiency of presenting
certain antigens may enhance the disease profile or may
lead to immune tolerance and, thereby, protection
against arthritis [23]. Therefore, this delicate balance
between disease susceptibility and tolerance can, in part,
be regulated by APC. Interestingly, it has been shown
that immature dendritic cells (DC) express cystatin C to
modulate cysteine protease activity as well as the expres-
sion of MHC class II molecules [24]. We have previously
shown that the DCs of the epidermis, Langerhans cells
(LC), are deficient in presenting CII but not other anti-
gens tested [25]. This phenomenon is an exception from
the rule, as DC are highly efficient in presenting antigens
and are regarded to be the dominating APC in priming
the immune system. Noteworthy, is that this poor pre-
sentation of CII could be overcome both in vitro and in
vivo by treating the LC with synthetic cysteine protease
inhibitors [26]. These synthetic cysteine protease inhibi-
t o r sa r eb e l i e v e dt oh a v eap r o t e a s ei n h i b i t o r ys p e c t r u m
similar to that of cystatin C. These studies, however,
were not able to directly assess the physiological role of
cystatin C. Hence, the aim of the present investigation
was to determine the role of cystatin C in vivo in terms
of arthritis susceptibility and severity.
Materials and methods
Mice
The targeted deletion of the cystatin C gene was origin-
ally made in an embryonic stem cell line derived from
the 129/Sv mouse strain, as described previously [27].
The targeted gene was then backcrossed onto the B10.Q
background 10 generations and then intercrossed. In all
investigations age and sex matched cystatin C-deficient
mice were compared with wild type B10.Q generated in
the final intercross. B10.Q mice originated from profes-
sor Jan Klein, Tübingen, Germany, and have been main-
tained within Professor R. Holmdal’s unit and this strain
is now denoted B10.Q/rhd. To exclude a role for 129
linked genes; F1 mice were generated by crossing cysta-
tin C-deficient mice or wild type B10.Q/rhd with the
129/Sv strain. All mice were housed at Unit for Medical
Inflammation Research, Lund University, and experi-
mental procedures were approved by the local (Lund-
Malmö region, Sweden) animal ethics organization.
Antigens
Rat CII was prepared from Swarm chondrosarcoma by
limited pepsin digestion, or from lathyritic chondrosar-
coma and purified as described earlier [28]. The CII
protein was dissolved in 0.1 M acetic acid and stored at
4°C. ConA (Sigma-Aldrich, Steinheim, Germany) was
dissolved in PBS and stored at -20°C.
Induction and evaluation of collagen induced arthritis
(CIA)
Mice 8 to 16 weeks of age were immunized at the base
of the tail with 100 μg/ml of CII emulsified 1:1 in Com-
plete Freunds Adjuvant (CFA) (Difco, BD, Franklin
Lakes, New York USA). A boost injection of CII 50 μg/
ml in Incomplete Freunds Adjuvants (IFA, Difco) was
given 35 days after immunization. Arthritis was evalu-
ated blindly using a scoring system based on the num-
ber of inflamed joints in each paw, inflammation
defined by swelling and redness. A maximum score of
three points per paw resulted in 0 to 12 points for each
mouse as has previously been described in detail [29].
Sera analyses
For quantification of anti-CII antibodies 96-well plates
(Corning Costar, Corning, New York, USA) were coated
overnight at 4°C with 10 μg/ml of CII in PBS. Washings
were performed using Tris-buffered saline (pH 7.4) con-
taining 0.1% Tween 20 (Tris/Tween). The sera were
diluted in wash buffer and tested in duplicate. The
amount of bound IgG antibodies was determined after
incubation with polyclonal goat anti-mouse IgG mAb
conjugated with horseradish peroxidase (Jackson, Immu-
noresearch Laboratories, West Grove, Pennsylvania,
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land) were used as chromogenic substrate and absor-
bance at 405 nm was measured in a Titertec multiscan
spectrophotormeter.
Induction and evaluation of CII antibody induced arthritis
(CAIA)
Arthritis was induced in three-to-five-month-old male
mice with an anti-CII antibody cocktail containing the
two antibodies; M2139 and CIIC1, binding to J1 and
C1
1 epitopes of CII, respectively. A total dose of 9.0 mg
was given each mouse i.v as described earlier [30]. On
Day 10, LPS (25 μg/mouse) was injected i.p in all mice
in order to enhance the incidence and severity of the
disease. Mice were examined daily for arthritis develop-
ment before and after LPS treatment for a total of 21
days. Arthritis was evaluated blindly based on the num-
ber of inflamed joints in each paw, where inflammation
was defined by swelling and redness. A maximum score
of three points per paw resulted in 0 to 12 points for
each mouse as has previously been described in detail
[29].
Delayed type hypersensitivity response (DTH)
Mice were immunized with 100 μg/ml of CII emulsified
in CFA at the base of the tail. On Day 10 after immuni-
zation, the mice were challenged with CII (dissolved in
0.1 M acetic acid) mixed with PBS and injected i.d. into
the right ear (30 μg in 0.02 M acetic acid per mouse).
The left ear was injected with the vehicle (PBS/0.02 M
acetic acid) alone and used as a control. Ear thickness
was measured 24, 48 and 72 hours after challenge and
the difference of ear thickness between right and left ear
was calculated.
T lymphocyte activation assay
T lymphocyte activation assay was performed using lym-
phocytes or splenocytes either as in vitro re-call assay
using immunized mice or as in vitro T cell priming
assay using naïve cells. In both cases B10.Q/rhd wild
type and cystatin C-deficient mice aged 8 to 16 weeks
were used. Single cell suspension of either naïve mice or
mice immunized 10 days prior (immunized as above in
CIA induction) were cultivated in Dulbecco’s modified
Eagle medium (DMEM, Gibco, Invitrogen Carlsbad,
California, USA) containing 10% FCS, 10 μM b-mercap-
toethanol, 10 mM HEPES, penicillin, and streptomycin
(complete media, cDMEM) in humidified incubator at
37°C in 7.5% CO2. Cells were stimulated with 25 μg/ml
of lathyritic type II collagen (only cells from immunized
mice) or with 3 μg/ml of ConA for 72 hours. An aliquot
of supernatant was taken after 24 h of stimulation in
order to detect IL-2 production. IL-2 and IFN-g
responses were measured by ELISA, with anti-IFN-g,
(5 μg/ml, clone An18 prepared in-house) anti-IL-2,
(2 μg/ml, clone JES-6-1A12 prepared in-house) as cap-
turing antibodies and biotinylated anti-IFN-g,( 0 . 6μg/
ml, clone R46-A2, MABTECH, Nacka Strand, Sweden),
and biotinylated anti IL-2 (1 μg/ml, clone JES6-5H4,
MABTECH) as detection antibody. 96-well plates (Corn-
ing Costar) were coated overnight at 4°C with capturing
antibodies, plates were then incubated with 2% BSA in
PBS for one hour to block unspecific binding. Samples
were added and incubated at room temperature for two
hours or at 4°C overnight. Finally, the plates were incu-
bated for two hours at room temperature with detecting
antibody in PBS containing 10% FCS and 0.1% Tween.
For detection the plates were incubated with europium-
avidin followed by enhancement buffer according to the
manufacturers’ instructions and fluorescent intensity
measured using a fluorometer (Wallac Oy EG & G, Per-
kinElmer, Waltham, Masschusetts, USA). Proliferation
was measured via Thymidine incorporation where the
cell culture was pulsed with (
3H) Thymidine for final 15
to 18 hours of cultivation. The cells were harvested in a
Micromate 196 cell harvester (Canberra Packard, Schwa-
dorf, Austria) and the radioactivity determined in a
Matrix™ direct b-counter (Canberra Packard).
Cell purification prior to T lymphocyte activation assay
In this system, splenic T cells from cystatin C-deficient
mice were co-cultured with splenic antigen-presenting
cells (APCs) either form cystatin C-deficient or wild
type mice, and wild type splenic T cells were co-cul-
tured with splenic APCs either from cystatin C-deficient
or wild type mice. T cells were separated from the APC
population by using the mouse CD4- and CD8 Dyna-
beads
® FlowComp™ system (Invitrogen™ Carlsbad,
California, USA), according to the manufacturer’s
instructions. The T cell population was 95% pure (as
observed by FACS, data not shown). Selected T cells
from each mouse were used individually. In order to
obtain the APC population, those cells that were CD4/
CD8 negative were subjected to an additional purifica-
tion step where they were first incubated with anti-CD4
biotinylated antibody (GK1.5, prepared in-house), fol-
lowed by Dynabeads
® Biotin Binder, Invitrogen™,i n
order to deplete the remaining T cells. This population
was then pooled and used as APCs in co-culture with
purified T cells. In all experiments 2.5 × 10
5 T cells/well
were co-cultured with 4 × 10
5 APCs in the same well.
The level of IL-2 production was measured after 24 h
and the IFN-g concentration was measured after 72 h of
stimulation with 3 μg/ml of ConA as described above.
Flow cytometry
Single cell suspension of spleens from naïve cystatin C-
deficient and wild type controls were prepared and red
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seeded (1 × 10
6 per well) into 96-well plates and stimu-
lated with either cDMEM alone or with 2 ug/mL of
ConA (Sigma-Aldrich) in cDMEM in a humidified incu-
bator at 37°C in 7.5% CO2 a n dc u l t i v a t e df o r2 4h o u r s
at 37°C. After 24 hours incubation or freshly prepared
splenocytes from cystatin C-deficient and wild type con-
trols cells were washed and Fc receptors blocked, using
24.G2 (prepared in-house), cells were stained for cell
specific and activation markers. T cell staining consisted
of: FITS-CD3 (clone 145-2C11), Pe-Cy5-CD4 (clone
GK1.5), PerCP-Cy5.5- CD8a (clone 53-6.7), APC-Cy7-
CD25 (clone PC61), PE-FR4 (clone TH6), PE-Cy7-CD69
(clone H1.2F3), and live cells were determined using
ViDye Violet. APC staining consisted of: Alexa Fluor
®
700-CD45R/B220 and CD19 (clones RA3-6B2 and 6D5
respectively), Pacific blue-CD11b (clone M1/70), Pe-
Cy7-CD11c (clone N418), Pe-Cy5-F4/80 (clone BM8),
APC-Cy7-Ly-6G/Ly-6C (GR-1, clone RB6-8C5), Alexa
Fluor
®488-MHC II (clone M5/114 purchased from BD,
Franklin Lakes, USA), PE-CD40 (stained intracellular
using BD intracellular staining kit according to the man-
ufacturers recommendations, clone IC10) or PE-CD80
(clone 16-10A1) Alexa Fluor
® 647-CD54 (ICAM, Clone
YN1/1.7.4) or Alexa Fluor
® 700-CD86 (clone GL-1). For
both dilution of antibodies and cells suspension, PBS
with 0.1% BSA (Sigma-Aldrich) and 0.01% sodium
Azide (Sigma-Aldrich) was used. However, for intracel-
lular staining against CD40 the BD intracellular staining
kit was used. All antibodies were purchased from BioLe-
gend (San Diego, California USA) unless indicated
otherwise and ViDye was purchased from Invitrogen.
All antibodies and Vidye were titrated using the accord-
ing to the manufacturers recommendations. The cells
were then analyzed by flow cytometry (LSRII; BD).
Antigen presentation assays
The antigen-presenting capacity of isolated APC was
determined by their ability to stimulate MHC A
q-
restricted T-cell hybridoma, namely HCQ.10 clone that
responds to CII and the galactose-peptide 256-270 [31].
Langerhans cells were prepared from mouse ears as
described earlier [32]. Bone marrow derived dendritic
cells (BMDCs) were prepared as described [33]. B cells
were separated from lymph nodes from mice immunized
10 days prior, using anti-mouse CD45R/B220 (clone
RA3-6B2) conjugated to microbeads, as described by the
manufacturer (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). Peritoneal exudate cells were collected by perito-
neal lavage where macrophages were enriched by
depleting B cells using anti-mouse CD45R/B220 (clone
RA3-6B2) microbeads (Miltenyi Biotec). Spleen DC were
isolated by dissecting the spleen into small pieces, with
5 ml DMEM containing antibiotics, 2% FCS, 0.5 mg/ml
of collagenase type IV (Worthington Biochemical Corp.
L a k e w o o dU S A )a n d5 0U / m lo fD N a s e( D e o x y r i b o n u -
clease 1 from bovine pancreas, Sigma-Aldrich), and
incubated at 37°C for 40 to 60 minutes with agitation.
Digested material was passed through a 70 μm cell strai-
ner (Falcon, BD Franklin Lakes USA), remaining tissue
pieces were minced through the strainer using a syringe
plunger. Cells were washed in PBS containing 2% FCS
and 2 mM EDTA. Non-specific binding was blocked
with anti-FcR mAb (clone 2.4.G2 prepared in-house) for
15 minutes on ice, and DC were enriched using positive
selection with anti-CD11c microbeads (Miltenyi Biotech)
and twice passed through LS magnetic column (Miltenyi
Biotech). Antigen presenting assay was performed by
co-cultivating T-cell hybridoma cells (50 × 10
3) with the
syngeneic APC and antigen in a total volume of 200 μl
in flat-bottomed 96-well plates (Nunc, Thermo Scienti-
fic, Rochester, New York, USA). After 24 h culture, 100
μl aliquots of the supernatants were cultured with 1 ×
10
5 cells/well of an IL-2 dependant murine cytotoxic T
cell line (CTLL), in a total volume of 200 μlf o r2 4h
and the CTLL cells were then pulsed with (
3H) Thymi-
dine for an additional 15 to 18 h. The cells were har-
vested in a Micromate 196-cell harvester (Canberra
Packard, Meriden, Connecticut, USA) and the radioac-
tivity determined in a Matrix™ direct b-counter (Can-
berra Packard). In addition, a sandwich ELISA was used
to determine IL-2 concentration as described above in
section “T lymphocyte activation assay assay”.
Statistical analysis
The Prism GraphPad software program (La Jolla, Cali-
fornia, USA) was used for the statistical analysis. All
mice were included for calculation for arthritis suscept-
ibility, whereas severity was determined with affected
mice only. The Mann-Whitney U test or Students t-test
was applied to evaluate statistical differences or for dis-
ease incidence Fisher’s exact test was used.
Results
Cystatin C-deficient mice have an increased incidence and
earlier onset of arthritis
To investigate the role of cystatin C in the development
of arthritis and, hence, its role in the immune response
towards CII, cystatin C-deficient, cystatin C heterozy-
gous- and cystatin C-sufficient B10.Q/rhd wild type lit-
termates were immunized with CII in CFA. The cystatin
C-deficient mice were more prone to develop arthritis
with a significantly higher incidence compared to the
wild type controls (Figure 1A, Table 1) arguing for a
protective role of cystatin C. Furthermore, cystatin C-
deficient mice developed arthritis earlier than the wild
type control mice, but there was no significant differ-
ence in the severity of arthritis as the maximal score
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prisingly, no difference concerning disease activity, nor
incidence, could be observed between homozygous and
heterozygous cystatin C-deficient mice. This could indi-
cate a dose level effect of cystatin C.
The CII-reactive antibody response, which is known to
correlate with disease onset and severity, was measured
at both day 35 and at day 115. Surprisingly, at day 34
there was a trend but no significant difference in anti-
CII antibody titers between cystatin C-deficient and wild
type controls in terms of anti-CII antibody titers (Figure
2A). However, at day 115, which reflects the chronic
phase of the disease, there was a significant difference
between cystatin C-deficient and wild type controls. In
fact, in the wild type mice, antibody titers at day 115
had dropped dramatically compared to day 34, indicat-
ing that the disease is in the process of resolving. How-
ever, this was not the case in the cystatin C-deficient
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Figure 1 Cystatin C-deficient mice have a higher incidence of arthritis but have a similar arthritic score. A,C y s t a t i nC - d e f i c i e n tm i c e
(Cyst C-/-, n = 17) had a greater cumulated arthritis incidence (that is, all mice that have shown signs of arthritis at any time point are included
as diseased individuals) compared to heterozygous (Cyst C-/+, n = 23) and wild type litters Cyst C+/+, n = 9). Data shown are from one
representative experiment out of two separate experiments (combined data shown in Table 1). * P-value < 0.05 as tested in Fisher’s exact test. B,
Cystatin C-deficient mice (n = 15) had a similar arthritic severity compared to heterozygous (n = 17) and wild type littermate controls (n =5 )
when affected mice were compared (mice were excluded if no clinical signs of arthritis was seen after 115 days post immunization).
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Genotype Arthritis incidence
#, number
with/number without (%)
Maximum
score, mean ±
SEM
Day of onset
†,
mean ± SEM
Disease
Duration
† mean
± SEM
Recovery
§ rate: number
recovered/number active
arthritis (%)
Area
under
curve
Cystatin C
-/-
25/8 (75*) 6.917 ± 0.72 44.57** ± 2.88 67.96* ± 5.29 4/21 (16*) 259.9
Cystatin C
+/-
23/12 (65) 7.955 ± 0.83 47.91** ± 4.23 54.41 ± 5.90 9/14 (39) 230.8
Cystatin C
+/+
12/13 (48) 6.500 ± 1.15 69.67 ± 7.78 38.08 ± 8.06 6/6 (50) 156.4
# Cumulative incidence, that is, all mice that have presented with arthritis. Chi-square test was used for determining statistical significance; † Mann Whitney test
was used for determining statistical significance; § Percent recovery was calculated by: (number of mice that had presented arthritis but did not have active
arthritis at Day 115 divided by the total number of mice that had presented arthritis during the 115-day period) multiplied by 100. Chi-square test was used for
determining statistical significance; * P-value less than 0.05; ** P-value less than 0.01.
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Figure 2 The anti-CII IgG antibody titers are elevated in the cystatin C-deficient mice. Mice were bled at Day 34 (A) before boost
immunization with CII/IFA, and at the end of the experiment at Day 115 (B). There was a statistically significant difference between the antibody
production of cystatin C-deficient mice (Cyst C -/-) and the wild type controls (Cyst C +/+) at Day 115. ** P-value < 0.01 as tested with Mann-
Whitney.
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day 34 (Figure 2B), indicating a sustained immune
response. Further, a chronic disease profile was observed
in the cystatin C-deficient mice compared to wild type
controls as there was a significantly longer disease dura-
tion and fewer mice recovered from arthritis (Table 1).
Hence, cystatin C clearly had a protective role in CIA,
as deficient mice were more prone to a chronic arthritis
and had a sustained autoreactive antibody response.
Effector phase of arthritis is similar between cystatin C-
deficient and control mice
Since the cystatin C-deficient mice displayed a more
sustained antibody synthesis compared to wild type lit-
termates (high antibody level at Day 115), the question
then arises whether cystatin C has an effect on priming
of the immune response or is more involved in the
inflammatory effector phase of the disease. The effector
phase of CIA can be observed separately from immune
priming by administering arthritogenic anti-CII antibo-
dies, that is, CAIA. Conversely to the effect of cystatin
C-deficiency in CIA, incidence of arthritis and day of
arthritis onset were not enhanced in cystatin C-deficient
mice in the CAIA model when compared to wild type
mice (Figure 3). This argues for cystatin C influencing
the autoimmune priming rather than the inflammatory
effector phase in CIA.
Enhanced delayed type 1 hypersensitivity (DTH) reaction
response in cystatin C-deficient mice
Since cystatin C-deficiency did not alter the inflamma-
tory effector phase and the fact that both cystatin C-
deficient and heterozygous mice developed arthritis ear-
lier than the wild type controls, there was an indication
that cystatin C-deficiency had an effect on priming the
immune response. We, therefore, wished to investigate
whether the T cell response to CII was altered in cysta-
tin C-deficient mice. The delayed-type hypersensitivity
(DTH) reaction is a T cell recall response to the immu-
nized antigen. Hence, mice were immunized with CII
and challenged in the ear with CII or PBS 10 days later.
Ear thickness was measured 48 and 72 hours after the
challenge. After 48 hours the cystatin C-deficient mice
already had an enhanced response (Figure 4A). These
results are in line with the initial findings of an
enhanced CIA disease profile of the cystatin C-deficient
mice.
The observed DTH effect is dependent on cystatin C and
not 129/Sv-linked genes
Since the cystatin C-deficient mice were originally pro-
duced in the 129/Sv strain we could not, despite exten-
sive backcrossing, exclude that 129/Sv genes in the
linked fragment containing the null-mutation had an
influence on our results. It was particularly important to
clarify the possible influence of such genes, since the
enhancing effects on CIA and anti-CII B and T cell
responses in vivo were also seen in heterozygous cysta-
tin C-deficient mice. Therefore, a DTH response was
tested in an F1 intercross between 129/Sv and B10.Q/
rhd wild type mice (controls) and compared to an F1
intercross between 129/Sva n dt h eB 1 0 . Q / r h db a c k -
crossed cystatin C-deficient mice (experimental group).
Reassuringly, the experimental group showed a signifi-
cantly stronger DTH-reaction than the corresponding
controls (Figure 4B). This shows that the cystatin C-
deficiency, and not a dominant 129/Sv-derived gene
effect, caused the observed enhanced DTH response.
Cystatin C-deficient APCs compared to wild type have a
greater propensity to stimulate cystatin C sufficient T
cells in T lymphocyte activation assay
With the finding that mice deficient in cystatin C had
an enhanced DTH, we wished to observe whether this
effect was due to T cells or APCs or a combination of
both. In order to investigate this we used an in vitro T
lymphocyte activation assay. Surprisingly, we observed
that the recall response of immunized cystatin C-defi-
cient lymphocytes or splenocytes did not differ signifi-
cantly from wild type cells in terms of T cell
proliferation, IL-2 or IFN-g production (data not
shown). Therefore, we considered the possibility that
there was a difference in the initial T cell priming and
not in the recall response in vitro.I n d e e d ,t h es p l e n o -
cytes from naïve cystatin C-deficient mice showed an
enhanced production in IL-2 after 24 h culture (Figure
5) but no difference in T cell proliferation or IFN-g pro-
duction after 72 h (data not shown) when stimulated
with a polyclonal stimulant ConA. Furthermore, if puri-
fied wild type T cells were co-cultured with purified
APC from cystatin C-deficient mice then IL-2 produc-
tion was enhanced compared to purified wild type T
cells co-cultured with wild type APC, but again no dif-
ference in IFN-g production was observed (Figure 5).
Interestingly, the T cells from cystatin C-deficient mice
displayed an enhanced IL-2 production at a significantly
higher level than cystatin C-sufficient T cells irrespective
of the genotype of the APC’s used. This indicates that
the T cells in cystatin C-deficient mice have a constitu-
tively lowered activation threshold or have been condi-
tioned in vivo, but the mechanism of this is beyond this
study.
DC’s from naïve cystatin C-deficient mice are more
activated
In view of the fact that the APCs from mice deficient
for cystatin C had an enhanced ability to stimulate T
cells in vitro, we were interested to see if there was a
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Page 7 of 14difference in expression of MHC class II or activation
markers between cystatin C-deficient and wild type
mice. The activation markers investigated included
CD80, CD86, CD40 and ICAM, which are co-stimula-
tory molecules known to aid in T cell activation. Sple-
nocytes of naïve mice as well as splenocytes stimulated
with ConA and media alone for 24 h were analyzed by
flow cytometry. In freshly isolated splenocytes from
naïve mice there was no difference observed in cell
composition with the similar percentage of B cells
(CD19 and CD45RB+), DC (CD11c
+, F4/80 antigen
- and
LyCG
-), macrophages (F4/80 antigen
+, CD11c
- and
Ly6G
-), neutrophils (CD11b
++ Ly6G
+), CD4
+ (CD3
+CD4
+) and CD8
+ (CD3
+CD8
+) T cells, and regulatory T cells
(CD4
+CD25
+FR4
+) between cystatin C-deficient and
wild type mice (data not shown).
Splenic DCs from naïve cystatin C-deficient mice, but
not any other of the investigated cell populations, had
an increased expression of MHCII, CD80 and CD86
(Figure 6A-C) but not ICAM or CD40 (data not shown)
compared to naïve wild type mice. Interestingly, upon
ConA stimulation, there was no statistical difference in
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Figure 3 Effector phase is similar between cystatin C-deficient and control mice. CAIA was induced with two monoclonal anti-CII
antibodies by i.v injection into cystatin C-deficient (Cyst C -/-, n = 6), cystatin C heterozygous (Cyst C -/+, n = 9) and WT littermate controls (Cyst
C +/+, n = 10). A, No significant difference was seen in incidence of arthritis. B, There was also no difference in arthritis severity when
comparing affected mice (Cyst C -/- n = 4, Cyst C -/+ n = 8, Cyst C +/+ n = 9, mice were excluded if no clinical signs of arthritis was seen after
20 days post antibody injection). The error bars indicate SEM.
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Page 8 of 14MHCII or CD80 expression and CD86 was in fact
expressed higher on wild type cells (data not shown).
However, the kinetics of this expression was not
determined.
The activation of T cells from the cystatin C-deficient
and wild type mice was also investigated and as we
would have predicted from the DTH results, and in
vitro T lymphocyte activation experiments, the cystatin
C-deficient CD4
+ T cells were more activated (higher
percentage of CD4
+ T cells expressed CD69, Figure 6D).
However, there was no significant increase in CD69
expressing CD8
+ cells (Figure 6E). In line with the ear-
lier results there was an increase in percent of CD4
+ T
cells (Figure 6F) after stimulation with ConA. There was
also a tendency toward increase in T cells (CD3
+ cells P
= 0.08) as well as in CD8+ T cells (P =0 . 1 8 ) ,b u tt h e
absolute number of cells was not calculated. Similar to
the freshly prepared splenocytes from cystatin C-
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Figure 4 Cystatin C-deficient mice show a stronger DTH reaction. A, Cystatin C-deficient mice (Cyst C -/-, n = 11) developed a significantly
stronger DTH reaction towards CII compared to the wild type controls (Cyst C +/+, n = 11) 48 h after challenge, and so did the heterozygous
cystatin C-deficient mice (Cyst C -/+, n = 11). B, The observed enhanced DTH was due to cystatin C-deficiency and not 129/Sv linked genes as
F1 intercross between 129/Sv x cystatin C-deficient mice (n = 12) had a significantly enhanced DTH compared to the F1 intercross between 129/
Sv x B10.Q/rhd (n = 12) 48 h after challenge. Significance was calculated with Mann-Whitney test where ** P-value < 0.01 and *** P-value <
0.001.
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Page 9 of 14deficient and wild type mice there was no difference in
cell composition with the similar percentage of B cells,
DC, macrophages, neutrophils and regulatory T cells in
ConA stimulated cells (data not shown).
Antigen presentation is not enhanced in APCs from
cystatin C-deficient mice
Cystatin C is an inhibitor of the cathepsins proteases that
have a crucial role in the cleaving of proteins for antigen
presentation; therefore, it is conceivable that cystatin C
would also have a prominent role in antigen presentation.
Furthermore, since naïve cystatin C-deficient DC
expressed a higher degree of MHC II molecules, it was
plausible that antigen presentation was enhanced in
cystatin C-deficient mice. Therefore, in order to remain
as close to the DTH setting, CII (without adjuvant) was
injected i.d in the ear of cystatin C-deficient and wild
type mice. Six hours later epidermal antigen presenting
cells were prepared, and tested for APC activity to CII
specific T cell hybridomas (HCQ.10). However, there was
no increased hybridoma response between the DCs
derived from cystatin C-deficient or wild type mice. This
was also the case when naïve skin epidermal APC’s,
spleen DC, isolated macrophages, B cells and bone
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Figure 5 Cystatin C-deficient APCs have a greater propensity to stimulate cystatin C-sufficient T cells. Splenocytes were prepared from
either cystatin C-deficient mice or wild type mice and stimulated in vitro with either media alone or with 2 ug/mL ConA (change in production
level (delta) is shown, where the response to media alone is deducted from the ConA response). Cystatin C-deficient splenocytes mice (CysC-/-)
had a significantly higher production of IL-2 (A) after 24 h Cystatin C-deficient APCs were able to enhance the IL-2 production of T cells from
wild type mice, where as there was no difference in IL-2 production in cystatin C-deficient T cells when co-cultured with either wild type (CysC
+/+) or cystatin C-deficient APCs (B). However, when wild type APCs where co-cultured with T cells then the cystatin C-deficient T cells
produced more IL-2 than wild type T cells. Six mice were used per group, statistical significance was calculated by Students t-test where * P-
value < 0.05 and ** P-value < 0.01.
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Page 10 of 14morrow derived DC were stimulated with CII in vitro
(data not shown). Therefore, the enhanced stimulatory
capacity of cystatin C-deficient APC is not due to a direct
increase in antigen processing.
Discussion
The natural inhibitor of cysteine proteases, cystatin C,
has been proposed to have a protective role in chronic
inflammatory disorders such as RA and atherosclerosis.
In the current study we demonstrate that cystatin C
plays an important role in the development of an auto-
immune B and T cell response to type II collagen,
which in turn leads to the early development of a
chronic CIA, rather than having an effect on the inflam-
matory effector phase. Our findings clearly show that
cystatin C has a direct autoimmune-regulating function
and to our knowledge, this has not been previously
demonstrated in an in vivo model.
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Figure 6 Cystatin C-deficient DCs have increased expression of MHCII and Co-stimulatory molecules, and more activated T cells.
Splenocytes from naïve mice or splenocytes stimulated with ConA or media were analyzed by flow cytometry. Naive DCs from cystatin C-
deficient (CysC-/-) mice expressed higher intensity of MHCII (A) CD80 (B) and CD86 (C). A greater percent of CD4
+ T cells expressed CD69 in
cystatin C-deficient mice than wild type mice (CysC+/+) when stimulated with ConA for 24 h (D) but not CD8+ T cells. (E), In line with this there
was a higher percent of CD4
+ T cells in cystatin C-deficient mice and a tendency for a higher percent of CD8
+ and total T cells (F). Six mice
were used per group, statistical significance was calculated by Students t-test where * P-value < 0.05 and ** P-value < 0.01.
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point whether cystatin C had a principal role in the
priming or effector inflammatory phase. The CAIA
model involves the administration of CII-specific antibo-
dies that bind to the joint cartilage resulting in an
inflammatory response that is driven by activated
macrophages and neutrophils [34]. The fact that CAIA
is driven by neutrophils was of particular interest as
cystatin C has been previously shown to effect neutro-
phil function [15,16]. Interestingly, the CAIA was not
enhanced in cystatin C-deficient mice, which strongly
indicated that the immune priming phase of CIA was
altered in cystatin C-deficient mice and that neutrophils
were not dramatically affected by cystatin C-deficiency.
In RA, cystatin C has been proposed to have an indir-
ect immuno-modulatory role via the removal of acute
phase protein serum amyloid A (SAA) [14]. In the cur-
rent study we cannot rule out that the lack of cystatin C
resulted in higher levels acute phase proteins and, in
particular SSA, as this was not measured. Notably, in
the CAIA model, LPS is administered to boost severity
and incidence of arthritis and it is well known that LPS
is one of the most potent enhancers of SSA. Still, there
was no enhanced disease profile between cystatin C-
deficient and WT mice. Therefore, it is most unlikely
that an excessive level of SSA was a prominent mechan-
ism in the exacerbated CIA disease profile of cystatin C-
deficient mice.
Since cystatin C-deficient mice did not have an
increased inflammatory effector phase, but had and ear-
lier onset with a higher incidence of arthritis, we wished
to investigate the priming phase of CIA. Hence, we used
a DTH reaction and cystatin C-deficient mice had a
robust increase in the recall response. Surprisingly, we
were unable to see any difference between cystatin C-
deficient and sufficient mice in T cell activation using
an in vitro T lymphocyte activation assay of immunized
mice. However, if naïve splenocytes were stimulated in
vitro with the polyclonal T cell activator ConA, then
there was a clear difference in IL-2 production, but in
vitro this difference was not reflected in T cell prolifera-
tion or IFN-g production. The fact that there seems to
be a contradiction between the in vivo and in vitro find-
ings is not uncommon and could be due to a vast range
of factors. ConA was used in these studies, as naïve T
cells are unresponsive to antigens such as CII without
prior immunization. However, ConA requires the pre-
sence and activation of APCs in order to stimulate naïve
T cells, and in this way mimics one aspect of the initial
priming of T cells in vivo. This use of ConA is not ideal
but gives a starting point to start to unravel the complex
mechanisms of cytstatin C. In addition to the initial
findings of altered IL-2 production, when we separated
the APC from the T cell compartment observed that the
APC from cystatin C-deficient mice had a greater pro-
pensity to stimulate T cells from wild type mice, but
that this was only in the first 24 h of T cell activation.
This implies that the APC compartment in cystatin C-
deficient mice is more activated. Interestingly, the T
cells from cystatin C-deficient mice responded more
than the wild type T cells, regardless of APC genotype.
These observations indicate that the APC from cystatin
C-deficient mice have a greater propensity to stimulate
T cells, but the cystatin C-deficiency also affects the T
cell activation level. These findings need to be further
investigated, and an obvious continuation would be the
use of CII specific TCR-transgenic mice that are defi-
cient in cystatin C, where the naïve T cell response to
CII can be directly investigated in vitro. Interestingly,
upon flow cytometry fine phenotyping of the cystatin C-
deficient mice, we observed that the DC compartment
was of a more activated phenotype than the wild type
controls. This finding further supports the notion that
the APC compartment of the cystatin C-deficient mice
is more activated.
An inherent problem when using knock-out mice is
the contamination of the genome with the genes derived
from the embryonic stem cell (ES) line used to create
the mouse. In the case of the cystatin C-deficient mouse
the ES line used was derived from the 129/Sv strain.
There is, then, even after 10 generations of backcrossing,
ar i s kt h a tt h eo b s e r v e dD T Ha n dC I Ae f f e c ti sd u et o
129/Sv genes linked to the targeted locus, and not due
to the cystatin C-deficiency. Therefore, we created an F1
cross between 129/Sv and B10.Q/rhd cystatin C-defi-
cient mice, and also an F1 generation between 129/Sv
and B10.Q/rhd mice. The DTH of the two F1 groups
showed an enhanced DTH reaction in the mice hetero-
zygous for cystatin C-deficiency and this was similar to
the DTH reaction of the pure B10.Q/rhd mice carrying
one allele of cystatin C-deficiency. Therefore, we could
be certain that the observed enhanced DTH response
was due to cystatin C-deficiency and not the surround-
ing 129/Sv genes.
There was very little difference in the cellular compo-
nent of the cystatin C-deficient and wild type mice
where the percentage of T cells and APCs was very
similar. Upon further flow cytometry investigations, it
could be seen that the DC population in naïve mice
were more activated with a higher expression of MHCII
and CD80 and CD86. In addition, when spleen cells
were stimulated with ConA for 24 h, T cells derived for
cystatin C-deficient mice were found to be more acti-
vated with a higher expression of CD69. Interestingly,
although DCs from cystatin C-deficient mice expressed
MHCII to a greater extent than wild type mice, there
was no distinct difference in antigen presentation
capacity.
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Cystatin C is an abundant protein that is expressed in
all nucleated cells, and has been found to be involved in
a range of biological functions; therefore, pinpointing
the fine mechanism of cystatin C in complex diseases is
difficult. However, this study demonstrates that cystatin
C has a protective role in CIA and that cystatin C-defi-
cient mice have a chronic disease profile. We postulate
here that one plausible mechanism of cystatin C-defi-
ciency could be the enhancement of T cell priming via a
more activated APC compartment. The enhanced T cell
priming would lead to T cells supplying B cell help that
in turn would lead to a greater production of autologous
antibodies and a chronic arthritis profile would develop.
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